Thermo Fisher Posts 3% Q2 Revenue Gain
Thermo Fisher Scientific (NYSE:TMO), a leader in life sciences tools and diagnostics, reported its second quarter 2025 results on July 23, 2025. The company outpaced expectations on both revenue and non-GAAP EPS, delivering $10.85 billion in revenue and $5.36 in non-GAAP EPS versus analyst estimates of $10.68 billion and $5.23, respectively. While revenue climbed by 3.0% from the prior year, operating margins tightened and free cash flow fell sharply, signaling growing pressures behind continued growth. Overall, the quarter was a mix of resiliency in top-line performance and new challenges in profitability, shaped by policy shifts and competitive dynamics.
Source: Analyst estimates for the quarter provided by FactSet.
Thermo Fisher Scientific enables research, diagnostics, and manufacturing for customers in the pharmaceutical, biotechnology, healthcare, and academic markets worldwide. Its portfolio spans scientific instruments, diagnostic tests, laboratory equipment, and specialty consumables. The company’s operations are divided into four main segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products Biopharma Services.
Source Fool.com
